Palvella Therapeutics (PVLA) Misses Q2 EPS by 36c

Palvella Therapeutics (NASDAQ: PVLA) reported Q2 EPS of ($1.52), $0.36 worse than the analyst estimate of ($1.16).

For earnings history and earnings-related data on Palvella Therapeutics (PVLA) click here.

You May Also Be Interested In

• U.S. and Denmark close in on a Greenland deal - Reuters
• Nscale files for IPO, seeks NYSE listing under ticker NSCL
• Lockheed Martin wins $871 million F-35 contract modification